- Home
- QLGN vs BJDX Comparison
QLGN vs BJDX Comparison
Compare QLGN & BJDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QLGN
- BJDX
- Stock Information
- Founded
- QLGN 1996
- BJDX 2015
- Country
- QLGN United States
- BJDX United States
- Employees
- QLGN N/A
- BJDX N/A
- Industry
- QLGN Biotechnology: Pharmaceutical Preparations
- BJDX Medical Specialities
- Sector
- QLGN Health Care
- BJDX Health Care
- Exchange
- QLGN Nasdaq
- BJDX Nasdaq
- Market Cap
- QLGN 2.2M
- BJDX 2.2M
- IPO Year
- QLGN N/A
- BJDX 2021
- Fundamental
- Price
- QLGN $3.48
- BJDX $1.67
- Analyst Decision
- QLGN
- BJDX
- Analyst Count
- QLGN 0
- BJDX 0
- Target Price
- QLGN N/A
- BJDX N/A
- AVG Volume (30 Days)
- QLGN 158.4K
- BJDX 3.4M
- Earning Date
- QLGN 05-06-2025
- BJDX 05-14-2025
- Dividend Yield
- QLGN N/A
- BJDX N/A
- EPS Growth
- QLGN N/A
- BJDX N/A
- EPS
- QLGN N/A
- BJDX N/A
- Revenue
- QLGN N/A
- BJDX N/A
- Revenue This Year
- QLGN N/A
- BJDX N/A
- Revenue Next Year
- QLGN N/A
- BJDX $55.56
- P/E Ratio
- QLGN N/A
- BJDX N/A
- Revenue Growth
- QLGN N/A
- BJDX N/A
- 52 Week Low
- QLGN $2.85
- BJDX $1.48
- 52 Week High
- QLGN $29.45
- BJDX $316.80
- Technical
- Relative Strength Index (RSI)
- QLGN 52.85
- BJDX 38.27
- Support Level
- QLGN $3.10
- BJDX $1.46
- Resistance Level
- QLGN $4.40
- BJDX $3.60
- Average True Range (ATR)
- QLGN 0.40
- BJDX 0.63
- MACD
- QLGN 0.05
- BJDX -0.13
- Stochastic Oscillator
- QLGN 40.32
- BJDX 2.40
About QLGN Qualigen Therapeutics Inc.
Qualigen Therapeutics Inc is a early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's lead program, QN-302, is an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells.
About BJDX Bluejay Diagnostics Inc.
Bluejay Diagnostics Inc is a medical diagnostics company. It is developing rapid tests using whole blood using its Symphony technology platform to improve patient outcomes in critical care settings. The company's first product, the Symphony IL-6 test, is for the monitoring of disease progression in critical care settings and is a clinically established inflammatory biomarker for the assessment of the severity of infection and inflammation across many disease indications, including sepsis.